ERBB2 and breast cancer: In HER2-positive breast cancer patients who have developed resistance toanti-HER2 therapies like trastuzumab or lapatinib, FASN inhibitors have shown promise in effectively reversing resistance, potentially serving as a sensitization strategy for HER2-targeted therapies35.